Physician profile
Ryan Lee Ung
NPI 1972948248
$2,022.21
in general payments reported to CMS, 2019-2025
15 companies · $30.47 in 2025
The $30.47 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.96 · 2020: $222 · 2021: $936 · 2022: $456 · 2023: $237 · 2024: $98.72 · 2025: $30.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $366.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $972.85 | 2020-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Abiomed | $347.18 | 2021 | |
| Novartis Pharmaceuticals Corporation | $168.48 | 2021-2023 | |
| Shockwave Medical, INC | $128.27 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $123.08 | 2021-2024 | Wainua |
| Amgen INC. | $41.96 | 2019 | |
| Livanova USA, INC. | $41.07 | 2022 | |
| Cvrx, INC. | $35.48 | 2023 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $33.96 | 2022 | |
| Kestra Medical Technology Services, INC. | $30.47 | 2025 | Assure Wcd |
| Bayer Healthcare Pharmaceuticals INC. | $22.59 | 2021 | |
| Daiichi Sankyo INC. | $20.10 | 2023 | Injectafer |
| Daxor Corporation | $19.45 | 2022 | |
| Haemonetics Corporation | $19.37 | 2024 | Teg5000 Hemostasis Analyzer |
| Picard Medical INC. | $17.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Ung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.